Non-Radiographic Axial Spondyloarthritis Therapeutic Market Report 2026

Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview

• Non-Radiographic Axial Spondyloarthritis Therapeutic market size has reached to $1.04 billion in 2025 • Expected to grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: Rising Clinical Trials Driving Growth In The Market Due To Increasing Demand For Personalized And Innovative Treatments • Market Trend: Emerging Innovations Driving Growth Through Advanced Dual-Pathway Immunomodulation • North America was the largest region in 2025.

What Is Covered Under Non-Radiographic Axial Spondyloarthritis Therapeutic Market?

Non-radiographic axial spondyloarthritis therapeutic refers to treatments aimed at managing symptoms and slowing disease progression in patients without visible joint damage on X-rays, primarily involving NSAIDs, biologic therapies (TNF and IL-17 inhibitors), and JAK inhibitors. The goal is to reduce inflammation, improve function, and prevent the development of radiographic changes in the spine and joints. The main types of non-radiographic axial spondyloarthritis therapies are non-steroidal anti-inflammatory drugs, biologics, small molecule therapies, and corticosteroids. Non-steroidal anti-inflammatory drugs (NSAIDs) are medications that reduce inflammation, pain, and fever by inhibiting enzymes involved in prostaglandin production. It is useful for various applications, such as oral, injectable, and topical, for various end users, including hospitals, ambulatory surgical centers, and homecare settings.

What Is The Non-Radiographic Axial Spondyloarthritis Therapeutic Market Growth Forecast?

The non-radiographic axial spondyloarthritis therapeutic market size is expected to see rapid growth in the next few years. It will grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing development of next-generation biologics, rising adoption of JAK inhibitor therapies, growing focus on personalized rheumatology care, expansion of early-stage intervention protocols, increasing patient awareness and diagnosis rates. Major trends in the forecast period include increasing adoption of biologic disease-modifying therapies, rising use of IL-17 and TNF inhibitors, growing focus on early disease intervention, expansion of targeted small molecule treatments, enhanced emphasis on long-term disease control.

What Is The Driver Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?

The increasing clinical trials are expected to propel the growth of the non-radiographic axial spondyloarthritis therapeutic market going forward. Clinical trials are research studies conducted on humans to evaluate the safety, effectiveness, and side effects of medical treatments or interventions. Clinical trials are increasing due to the growing demand for personalized and innovative treatments that require rigorous testing for safety and efficacy. Clinical trials support non-radiographic axial spondyloarthritis therapeutics by providing evidence-based validation of treatment efficacy and safety in early-stage disease, guiding regulatory approvals and clinical adoption. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based government and NHS organisation to improve patient access to new treatments, reported that the total number of industry clinical trials initiated in the UK increased, up from 411 trials in 2022 to 426 in 2023. Therefore, the increasing clinical trials are driving the growth of the non-radiographic axial spondyloarthritis therapeutic industry.

Key Players In The Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market

Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc, Johnson and Johnson, AbbVie Inc, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc, Biogen Inc, Daiichi Sankyo Company Limited, UCB SA, Mochida Pharmaceutical Co Ltd, Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co Ltd, Qyuns Therapeutics Co Ltd, Sandoz Group AG, Boehringer Ingelheim GmbH, Roche Holding AG

Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market Trends and Insights

Major companies operating in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market are focusing on developing innovative solutions such as dual IL-17A/IL-17F biologic inhibitors and high-convenience delivery formats to address rising diagnosis rates, earlier disease recognition, the need for faster and deeper inflammatory control, and patient preference for less frequent or more convenient dosing. Dual IL-17A/IL-17F biologic inhibitors involve monoclonal antibodies that selectively and simultaneously block the cytokines IL-17A and IL-17F, which helps manage nr-axSpA by reducing inflammation, pain, stiffness, and structural progression. For instance, in September 2024, UCB S.A. (Union Chimique Belge Société Anonyme), a Belgium-based global biopharmaceutical company, launched BIMZELX in the U.S. for adults with active nr-axSpA following FDA approval. BIMZELX is a humanized IgG monoclonal antibody designed to neutralize both IL-17A and IL-17F, providing broader suppression of IL-17-mediated pathways compared with traditional TNF inhibitors or single-target IL-17 therapies. In addition to nr-axSpA, BIMZELX is also indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, addressing the evolving treatment needs of patients with inflammatory diseases.

What Are Latest Mergers And Acquisitions In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired DICE Therapeutics for an undisclosed amount. With this acquisition, Eli Lilly aims to strengthen its immunology portfolio by incorporating DICE's promising oral IL-17 inhibitors for autoimmune diseases and enhance its ability to address chronic inflammatory conditions with innovative, patient-friendly oral therapies. DICE Therapeutics is a US-based biopharmaceutical company that offers oral IL-17 antagonists, including DC-806 and DC-853, for treating non-radiographic axial spondyloarthritis (nr-axSpA) and other autoimmune diseases.

What Defines the Non-Radiographic Axial Spondyloarthritis Therapeutic Market?

The non-radiographic axial spondyloarthritis therapeutic market consists of sales of TNF inhibitors, JAK inhibitors, non-steroidal anti-inflammatory drugs, and IL-23 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Radiographic Axial Spondyloarthritis Therapeutic Market Report 2026?

The non-radiographic axial spondyloarthritis therapeutic market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-radiographic axial spondyloarthritis therapeutic industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.